These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20676141)

  • 21. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment.
    Yang Y; Zhao Y; Liao W; Yang J; Wu L; Zheng Z; Yu Y; Zhou W; Li L; Feng J; Wang H; Zhu WG
    Neoplasia; 2009 Apr; 11(4):313-24. PubMed ID: 19308286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
    Lindemann RK; Newbold A; Whitecross KF; Cluse LA; Frew AJ; Ellis L; Williams S; Wiegmans AP; Dear AE; Scott CL; Pellegrini M; Wei A; Richon VM; Marks PA; Lowe SW; Smyth MJ; Johnstone RW
    Proc Natl Acad Sci U S A; 2007 May; 104(19):8071-6. PubMed ID: 17470784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
    Heinicke U; Fulda S
    Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA).
    Henderson C; Mizzau M; Paroni G; Maestro R; Schneider C; Brancolini C
    J Biol Chem; 2003 Apr; 278(14):12579-89. PubMed ID: 12556448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.
    De Bruyne E; Bos TJ; Schuit F; Van Valckenborgh E; Menu E; Thorrez L; Atadja P; Jernberg-Wiklund H; Vanderkerken K
    Blood; 2010 Mar; 115(12):2430-40. PubMed ID: 20086250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
    Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.
    Labisso WL; Wirth M; Stojanovic N; Stauber RH; Schnieke A; Schmid RM; Krämer OH; Saur D; Schneider G
    Cell Cycle; 2012 Apr; 11(8):1593-602. PubMed ID: 22456335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
    Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
    Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the regulatory machinery of BIM for cancer therapy.
    Harada H; Grant S
    Crit Rev Eukaryot Gene Expr; 2012; 22(2):117-29. PubMed ID: 22856430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo.
    Zheng L; Fu Y; Zhuang L; Gai R; Ma J; Lou J; Zhu H; He Q; Yang B
    Int J Cancer; 2014 Oct; 135(7):1721-32. PubMed ID: 24615207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
    Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
    Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
    Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
    PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim.
    Paschos K; Smith P; Anderton E; Middeldorp JM; White RE; Allday MJ
    PLoS Pathog; 2009 Jun; 5(6):e1000492. PubMed ID: 19557159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.
    Shao Y; Aplin AE
    Cell Death Differ; 2012 Dec; 19(12):2029-39. PubMed ID: 22858545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity.
    Tan J; Zhuang L; Jiang X; Yang KK; Karuturi KM; Yu Q
    J Biol Chem; 2006 Apr; 281(15):10508-15. PubMed ID: 16476732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
    Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
    J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.